Lanadut (Dutasteride)

Dutasteride blocks both type I and type II 5‑alpha‑reductase enzymes, the proteins that convert testosterone into dihydrotestosterone (DHT). By lowering DHT levels, the drug reduces androgen‑driven growth of prostate tissue and diminishes the hormonal stimulus that contributes to male pattern hair loss.

The exact dosage of Lanadut is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Healthcare professionals follow local prescribing guidelines and adjust the dose as needed; patients should follow the prescriber’s instructions precisely.

Dutasteride is classified as Pregnancy Category X, meaning it is contraindicated in women who are pregnant or may become pregnant because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as it may be excreted in breast milk and affect a nursing infant.

To request Lanadut, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both dutasteride and finasteride inhibit 5‑alpha‑reductase, but dutasteride blocks both type I and type II isoenzymes, offering a more comprehensive reduction of DHT. Consequently, dutasteride generally produces a greater decrease in prostate volume and may be more effective for severe BPH, while finasteride is often used for milder cases and has a longer market history.

Lanadut should be stored at room temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Lanadut is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious but rare risks include severe allergic reactions such as rash, swelling, or anaphylaxis; the development of male breast cancer; and significant liver enzyme elevations indicating possible hepatic injury. Patients should seek immediate medical attention if they notice any signs of these conditions.

Lanadut should not be used by women, especially those who are pregnant, planning to become pregnant, or breastfeeding. It is also contraindicated in children and adolescents, and in men with known hypersensitivity to dutasteride or any of the tablet’s excipients.